Radiopharmaceutical developer ImaginAb has raised almost $13 million in funding to support the company's growth and further development of its CD8 Immuno-PET agent.
Immuno-PET is an antibody fragment (minibody) labeled with zirconium-89 that binds to the CD8 receptor on human T cells and is being developed for quantitative, noninvasive PET imaging of CD8 T cells in patients.
The company said the funding will be used to continue and expand clinical trials of CD8 Immuno-PET that are underway in over 20 hospitals in North America, Europe, and Australia.